subscribeSubscribe
Lipocine Announces Regulatory Pathway on Oral LPCN 1154 for PPD

Lipocine Announces Regulatory Pathway on Oral LPCN 1154 for PPD
PRNEWSWIRE
15 Sep 2022
Share Share
Sage Therapeutics to halve its total workforce in radical cost-cutting move

Sage Therapeutics to halve its total workforce in radical cost-cutting move
PHARMAFILE
08 Apr 2020
Share Share
Blasted by PhIII failure, a struggling Sage axes 340 staffers and bunkers down

Blasted by PhIII failure, a struggling Sage axes 340 staffers and bunkers down
John Carroll ENDPTS
08 Apr 2020
Share Share
Sage`s new drug starts slow, as Wall Street waits for depression data

Sage`s new drug starts slow, as Wall Street waits for depression data
BIOPHARMADIVE
14 Nov 2019
Share Share
Sage strategy for postpartum depression drug Zulresso keys on patient support

Sage strategy for postpartum depression drug Zulresso keys on patient support
Beth Snyder FIERCE PHARMA
01 Jul 2019
Share Share
FDA approves first drug specifically for postpartum depression

FDA approves first drug specifically for postpartum depression
Maggie Lynch IN-PHARMATECHNOLOGIST
25 Mar 2019
Share Share
FDA approves first treatment for postpartum depression

FDA approves first treatment for postpartum depression
FDA
22 Mar 2019
Share Share
Sage gets US approval for first postpartum depression therapy

Sage gets US approval for first postpartum depression therapy
NIH
21 Mar 2019
Share Share
Sage raises $575m ahead of FDA review date for Zulresso

Sage raises $575m ahead of FDA review date for Zulresso
Phil Taylor PMLIVE
28 Feb 2019
Share Share
Sage Therapeutics Receives PDUFA Extension for ZULRESSO™ (brexanolone) Injection

Sage Therapeutics Receives PDUFA Extension for ZULRESSO™ (brexanolone) Injection
BUSINESSWIRE
21 Nov 2018
Share Share